StemCells Inc. (STEM) Interim Results Show Improvement In Visual Function And Slowing Of Disease Progression In Phase 1/2 Dry AMD Trial
6/19/2014 8:40:53 AM
NEWARK, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.
Help employers find you! Check out all the jobs and post your resume.
comments powered by